An 8 Day, Randomised, Double Blind, 3-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Fluticasone Propionate in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR).
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Fluticasone propionate; GSK 256066
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Mar 2008 New trial record.